Takeda investors unhappy with preliminary Shire deal; New drug sales drive Amgen earnings; Novartis debuts mobile app for eye disease study.
The billionaire recently stepped down as chairman of Vivendi.
But threats to the industry loom as brands take work in-house.
HealthyWomen's CEO dishes on the #KeeptheCare initiative, and the rigors of activism and advocacy in the digital age.
The firm's Narcan product is more than just a lifesaving treatment for opioid overdose. It's a brilliant, salient campaign, as well.
Amgen and Novartis enlisted Arnold Worldwide, Wavemaker, and Starcom Media Group for its Speak Your Migraine campaign.
Express Scripts pressures Amgen on migraine medicine list price; Takeda, Shire get closer to deal; Sanofi R&D chief steps down.
Takeda makes higher offer for Shire; Prothena pulls plug on AL amyloidosis drug; Henry Schein to spin off animal health unit.
A deal with Sandoz to lead the global launch of Pear's two lead products puts marketing muscle behind the nascent class of 'prescription digital therapeutics.'
Novocure and Glue Advertising put on a Facebook Live event promoting the cancer treatment Optune in March.
Allergan reverses course on Shire deal; Merck seeks partners for cancer, immune system drugs; J&J diversified vision portfolio and it's paying off.
Procter & Gamble said its $4.2 billion acquisition of German firm Merck's consumer health division was about allowing it to respond to the changing demands of an aging world.
Nearly a quarter (22%) of all marcomms M&A deals involved private-equity funds — double the 11% seen in the last two quarters of 2017.
Allergan enters bidding war for Shire; Opioid prescriptions drop in 2017; Novartis Q1 numbers disappoint.
WPP's joint chief operating officers Mark Read and Andrew Scott have said they do not believe a break-up of the ad group makes sense.